Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Research & Development of $77.6 million for Q1 2026, up 1.04% year-over-year from $76.8 million in Q1 2025, and up 676.31% quarter-over-quarter from $10.0 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Research & Development history runs 14 years deep, the most recent figure standing at $77.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 1.04% year-over-year to $77.6 million; the TTM figure through Mar 2026 stood at $260.5 million (down 4.97% YoY), while the FY2025 annual figure was $338.9 million, up 42.26% from the prior year.
- Research & Development for Q1 2026 stood at $77.6 million, up from $10.0 million in the prior quarter.
- The five-year high for Research & Development was $86.6 million in Q2 2025, with the low at $5.6 million in Q4 2022.
- The 5-year median for Research & Development is $40.9 million (2024), against an average of $47.2 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development jumped 588.52% in 2023, then plunged 86.1% in 2025.
- Viridian Therapeutics, Inc.\DE's Research & Development stood at $5.6 million in 2022, then surged by 588.52% to $38.6 million in 2023, then jumped by 86.63% to $72.0 million in 2024, then slumped by 86.1% to $10.0 million in 2025, then jumped by 676.31% to $77.6 million in 2026.
- Business Quant data shows VRDN's Research & Development at $77.6 million in Q1 2026, $10.0 million in Q4 2025, and $86.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 71.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.58 Mn |
| Mar 31, 2026 | 77.63 Mn |
| Dec 31, 2025 | 10.00 Mn |
| Sep 30, 2025 | 86.26 Mn |
| Jun 30, 2025 | 86.63 Mn |
| Mar 31, 2025 | 76.84 Mn |
| Dec 31, 2024 | 71.96 Mn |
| Sep 30, 2024 | 69.16 Mn |
| Jun 30, 2024 | 56.19 Mn |
| Mar 31, 2024 | 40.94 Mn |
| Dec 31, 2023 | 38.56 Mn |
| Sep 30, 2023 | 30.39 Mn |
| Jun 30, 2023 | 40.08 Mn |
| Mar 31, 2023 | 50.74 Mn |
| Dec 31, 2022 | 5.60 Mn |
| Sep 30, 2022 | 22.12 Mn |
| Jun 30, 2022 | 21.71 Mn |
| Mar 31, 2022 | 17.75 Mn |
| Dec 31, 2021 | 22.39 Mn |
| Sep 30, 2021 | 8.12 Mn |